|
|
Thomson Financial Business Description:
| The Group's principal activity is to carry out research and development in the field of healthcare and biotechnology. It's research focuses on the development of therapeutic peptides targeting endocrine and metabolic disorders. It conducts its activities in two segments: the development of therapeutic peptides and cellular therapy. It's products are currently at various stages of development, ranging from discovery to Phase II clinical trials and target catabolic diseases as well as osteoporosis and diabetes. It continued Phase II clinical development program for the lead product ThGRF, a growth hormone-releasing factor analogue, the anabolic or regenerative potential of which could be applied to a large number of clinical indications. It owns the proprietary technology named Exopep. The Group has entered into an agreement with the American subsidiary of Bachem AG of Switzerland a company specializing in manufacture of peptides. |
|
Alacra Alerts:
 
|
Receive alerts on the latest reports on Theratechnologies Inc.
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
|
|
